2022-RA-708-ESGO Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy?

Autor:	Floor Backes, Tirza Areli Calderón Boyle, Jessica Perhanidis, Jonathan Lim, Linda Kalilani, Jean A Hurteau, Amanda Golembesky, Ritu Salani
Rok vydání:	2022
Zdroj:	Ovarian cancer.
DOI:	10.1136/ijgc-2022-esgo.551
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5d7772b5d950f89d9c78a58df32690de https://doi.org/10.1136/ijgc-2022-esgo.551 Zobrazit plný text záznamu